S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in
(Ad)
Billions of dollars are pouring into one long-ignored asset Goldman Sachs expects will soar in the first quarter of 2020. Go here to see hard-asset expert's #1 way to play this massive shift before it turns into a runaway train.

NASDAQ:KMDA - Kamada Stock Price, Forecast & News

$6.52
+0.02 (+0.31 %)
(As of 01/20/2020 11:05 AM ET)
Today's Range
$6.41
Now: $6.52
$6.62
50-Day Range
$6.01
MA: $6.96
$7.70
52-Week Range
$4.91
Now: $6.52
$8.00
Volume71,133 shs
Average Volume52,803 shs
Market Capitalization$262.50 million
P/E Ratio7.67
Dividend YieldN/A
Beta1.3
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KMDA
CUSIPN/A
Phone972-8940-6472

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$114.47 million
Cash Flow$0.65 per share
Book Value$2.79 per share

Profitability

Net Income$22.30 million

Miscellaneous

Employees408
Market Cap$262.50 million
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable

Receive KMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.


Kamada (NASDAQ:KMDA) Frequently Asked Questions

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) announced its earnings results on Wednesday, November, 13th. The biotechnology company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.05. The biotechnology company had revenue of $33.07 million for the quarter, compared to the consensus estimate of $28.94 million. Kamada had a return on equity of 28.62% and a net margin of 24.16%. View Kamada's Earnings History.

When is Kamada's next earnings date?

Kamada is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Kamada.

What guidance has Kamada issued on next quarter's earnings?

Kamada issued an update on its FY 2019 Pre-Market earnings guidance on Tuesday, January, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $126.5-127.5 million, compared to the consensus revenue estimate of $130.47 million.

What price target have analysts set for KMDA?

2 brokerages have issued 1 year price targets for Kamada's shares. Their forecasts range from $7.00 to $11.00. On average, they expect Kamada's stock price to reach $9.00 in the next year. This suggests a possible upside of 38.0% from the stock's current price. View Analyst Price Targets for Kamada.

What is the consensus analysts' recommendation for Kamada?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kamada.

What are Wall Street analysts saying about Kamada stock?

Here are some recent quotes from research analysts about Kamada stock:
  • 1. According to Zacks Investment Research, "Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. " (8/13/2019)
  • 2. HC Wainwright analysts commented, "Our price target of $11/share is based on an equally weighted composite of: (a) $14.26/share, as a 35x multiple of taxed and diluted FY23 GAAP EPS of $0.84 discounted back to and (b) an NPV of $8.1/share (discount rate 12%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of AAT (IV and IH) to achieve peak commercial revenue estimates in our model (due to market size, penetration rates, and/ or pricing); (2) failure of IH-AAT in clinical studies; (3) failure of IH-AAT to secure regulatory approval; and (4) other potential pipeline failures." (8/7/2019)

Has Kamada been receiving favorable news coverage?

Headlines about KMDA stock have trended positive on Monday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Kamada earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Kamada.

Are investors shorting Kamada?

Kamada saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 6,700 shares, a decrease of 47.7% from the December 15th total of 12,800 shares. Based on an average daily trading volume, of 58,500 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the company's shares are sold short. View Kamada's Current Options Chain.

Who are some of Kamada's key competitors?

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Zoetis (ZTS) and Micron Technology (MU).

Who are Kamada's key executives?

Kamada's management team includes the folowing people:
  • Mr. Amir London, Chief Exec. Officer (Age 50)
  • Mr. Chaime Orlev, Chief Financial Officer (Age 49)
  • Mr. Eran Nir, VP of Operations & Plant Mang. (Age 46)
  • Mr. David Tsur, Co-Founder & Active Deputy Chairman (Age 68)
  • Dr. Naveh Tov M.D., Ph.D., VP of Clinical Devel. & Medical Director for Pulmonary Diseases (Age 55)

How do I buy shares of Kamada?

Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $6.52.

How big of a company is Kamada?

Kamada has a market capitalization of $262.50 million and generates $114.47 million in revenue each year. The biotechnology company earns $22.30 million in net income (profit) each year or $0.55 on an earnings per share basis. Kamada employs 408 workers across the globe.View Additional Information About Kamada.

What is Kamada's official website?

The official website for Kamada is http://www.kamada.com/.

How can I contact Kamada?

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]


MarketBeat Community Rating for Kamada (NASDAQ KMDA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  218 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  482
MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe KMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Featured Article: What are economic reports?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel